Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-12-05Clinical Trial Update: Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy [Phase 2]
A Phase 2 clinical trial is evaluating the combination of tremelimumab and durvalumab with concomitant radiotherapy in advanced non-small ce…
-
CLINICAL_TRIALS trial_result · 2024-12-04Clinical Trial Update: A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC [Phase 2]
A single-arm Phase 2 trial evaluating the efficacy and safety of trastuzumab deruxtecan in patients with HER2-mutant non-small cell lung can…
-
CLINICAL_TRIALS trial_result · 2024-12-04Clinical Trial Update: Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients [Phase 2]
This update reports results from a Phase 2 trial of nivolumab as neo-adjuvant immunotherapy in non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2024-12-03Clinical Trial Update: The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial [Phase 2]
A Phase 2 trial update reports completion and results posting for the selective personalized radio-immunotherapy approach in locally advance…
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer [Phase 3]
Phase 3 trial comparing tislelizumab to chemotherapy in advanced non-squamous non-small cell lung cancer has completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC [Phase 1]
A Phase 1 trial evaluating atovaquone in combination with radical chemoradiotherapy for locally advanced non-small cell lung cancer has comp…
-
CLINICAL_TRIALS trial_result · 2024-11-25Clinical Trial Update: A Study of NDI 1150-101 in Patients With Solid Tumors [Phase 1, Phase 2]
Nimbus Saturn, Inc. is conducting a Phase 1/2 trial of NDI 1150-101 in patients with solid tumors, including renal cell carcinoma, gastric c…
-
CLINICAL_TRIALS trial_result · 2024-11-22Clinical Trial Update: Supportive Care Mobile Application for Patients With NSCLC [NA]
The document provides an update on a completed clinical trial evaluating a supportive care mobile application for patients with non-small ce…
-
CLINICAL_TRIALS trial_result · 2024-11-21Clinical Trial Update: A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer [Phase 2]
Phase 2 study comparing preferences for subcutaneous versus intravenous atezolizumab in non-small cell lung cancer has completed, with resul…
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]
Phase 1 study of ASP8273 in EGFR-mutated non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations [Phase 2]
Phase 2 trial of ASP8273 in EGFR-mutant, EGFR-TKI–naïve non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation
This clinical trial is evaluating the clinical performance of LifeOS Digital PCR Liquid Biopsy Kits for detecting the EGFR T790M mutation in…
-
CLINICAL_TRIALS trial_result · 2024-11-15Clinical Trial Update: A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors [Phase 1]
Phase 1 study of Pegilodecakin (LY3500518) in patients with advanced solid tumors has completed, spanning multiple indications including mel…
-
CLINICAL_TRIALS trial_result · 2024-11-14Clinical Trial Update: A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]
A Phase 1 dose-escalation study of ASP8273 in patients with non-small cell lung cancer harboring EGFR mutations has completed.
-
CLINICAL_TRIALS trial_result · 2024-11-14Clinical Trial Update: An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1, Phase 2]
This update indicates that the Phase 1/Phase 2 trial of ASP8273 in EGFR-mutant non-small cell lung cancer has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases [Phase 2, Phase 3]
Phase 2/3 study evaluating the safety and efficacy of serplulimab plus bevacizumab and chemotherapy in non-small cell lung cancer patients w…
-
CLINICAL_TRIALS trial_result · 2024-11-13Clinical Trial Update: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations [Phase 2]
Phase 2 basket trial evaluating tucatinib in combination with trastuzumab across HER2-altered solid tumors, with results posted for several …
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: Long Term Safety Observation of Crizotinib in Chinese NSCLC Population [Phase 4]
A Phase 4 long-term safety observation of crizotinib in Chinese patients with ALK- or ROS1-positive non-small cell lung cancer has been term…
-
CLINICAL_TRIALS trial_result · 2024-11-08Clinical Trial Update: Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC [Phase 4]
Phase 4 study assessing the safety of durvalumab in Indian adults with unresectable non-small cell lung cancer. The study has completed and …
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: TEIPP Immunotherapy in Patients With NSCLC [Phase 1, Phase 2]
This clinical trial update indicates completion of Phase 1 and Phase 2 testing of TEIPP immunotherapy in patients with non-small cell lung c…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors [Phase 1]
This Phase 1 update describes the dose-escalation and expansion study of AROG4-01 in patients with advanced solid tumors, including mesothel…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC [NA]
This clinical trial update reports the completion of a study evaluating peripheral immune cell activity in patients with early-stage non-sma…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination [Phase 1]
Pfizer's Phase 1 study of PF-07329640, given alone or in combination, in advanced/metastatic solid tumors including non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2024-11-06Clinical Trial Update: Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment [Phase 1]
A Phase 1 trial evaluating safety of immunotherapy induction with tremelimumab and durvalumab before chemoradiotherapy and/or resection in S…
-
CLINICAL_TRIALS trial_result · 2024-11-05Clinical Trial Update: Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients [Phase 2]
A Phase 2 trial in ALK-positive non-small cell lung cancer evaluates the activity of lorlatinib in relation to ALK resistance mutations dete…